Association of Increased Pulmonary Interleukin-6 with the Priming Effect of Intra-Amniotic Lipopolysaccharide on Hyperoxic Lung Injury in a Rat Model of Bronchopulmonary DysplasiaKim D.-H.a, c · Choi C.W.b, c · Kim E.-K.c · Kim H.-S.c · Kim B.I.b, c · Choi J.-H.c · Lee M.J.d · Yang E.G.d
aDepartment of Pediatrics, Dongguk University Ilsan Hospital, and bClinical Research Institute, Seoul National University Bundang Hospital, Gyeonggi-do, cDepartment of Pediatrics, Seoul National University College of Medicine, and dLife Sciences Research Division, Korea Institute of Science and Technology, Seoul, Korea
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: The authors previously demonstrated the priming effect of intra-amniotic lipopolysaccharide (LPS) on hyperoxic lung injury in a rat model of bronchopulmonary dysplasia (BPD). Objectives: To investigate the mechanism underlying this priming effect by determining biochemical profiles in a rat model of BPD. Methods: The rat model involved intra-amniotic LPS administration and postnatal hyperoxia (85%). The mRNA expressions of interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2), basic fibroblast growth factor (bFGF), and transforming growth factor β1 (TGF-β1), as well as the protein levels of IL-6, VEGF, and protein carbonyl in lung tissue were compared between the LPS plus hyperoxia, the LPS only, the hyperoxia only, and the control groups. Results: Morphometric analysis of lung tissues demonstrated that alveolarization was significantly inhibited only in the LPS plus hyperoxia group. IL-6 protein levels and its mRNA expression in the lungs were significantly increased only in the LPS plus hyperoxia group. Neither LPS nor hyperoxia increased IL-6 in the lungs independently. bFGF mRNA expression was significantly decreased in the LPS-treated groups. VEGF protein levels were significantly reduced by hyperoxia, whereas protein carbonyl levels were increased by intra-amniotic LPS or hyperoxia. No additional significant change to VEGF or protein carbonyl levels was produced by intra-amniotic LPS or hyperoxia. There were no significant differences in the mRNA expressions of VEGF, VEGFR-2, and TGF-β1. Conclusions: The priming effect of intra-amniotic LPS on hyperoxic lung injury may be associated with IL-6 elevation in the lungs.
© 2009 S. Karger AG, Basel
- Yoon BH, Romero R, Kim KS, Park JS, Ki SH, Kim BI, Jun JK: A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1999;181:773–779.
- Speer CP: Inflammation and bronchopulmonary dysplasia. Semin Neonatol 2003;8:29–38.
- Jobe AH: Antenatal factors and the development of bronchopulmonary dysplasia. Semin Neonatol 2003;8:9–17.
- Van Marter LJ, Dammann O, Allred EN, Leviton A, Pagano M, Moore M, Martin C: Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in preterm infants. J Pediatr 2002;140:171–176.
- Ikegami M, Jobe AH: Postnatal lung inflammation increased by ventilation or preterm lambs exposed antenatally to E. coli endotoxin. Pediatr Res 2002;52:356–362.
- Choi CW, Kim BI, Hong JS, Kim EK, Kim HS, Choi JH: Bronchopulmonary dysplasia in a rat model induced by intra-amniotic inflammation and postnatal hyperoxia: morphometric aspects. Pediatr Res 2009;65:R323–R327.
- Thébaud B: Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity. Neonatology 2007;91:291–297.
- Saugstad OD: Bronchopulmonary dysplasia-oxidative stress and antioxidants. Semin Neonatol 2003;8:39–49.
Jankov RP, Keith Tanswell A: Growth factors, postnatal lung growth and bronchopulmonary dysplasia. Paediatr Respir Rev 2004;(suppl A):S265–S275.
- Hosford GE, Olson DM: Effects of hyperoxia on VEGF, its receptors, and HIF-2α in the newborn rat lung. Am J Physiol 2003;285:L161–L168.
Kallapur SG, Bachurski CJ, Le Cras TD, Joshi SN, Ikegami M, Jobe AH: Vascular changes after intra-amniotic endotoxin in preterm lamb lungs. Am J Physiol 2004;287:L1178–L1185.
Kunzmann S, Speer CP, Jobe AH, Kramer BW: Antenatal inflammation induced TGF-β1 but suppressed CTGF in preterm lungs Am J Physiol 2007;292:L223–L231.
- Bourbon J, Boucherat O, Chailley-Heu B, Delacourt C: Control mechanisms of lung alveolar development and their disorders in bronchopulmonary dysplasia. Pediatr Res 2005;57:38R–46R.
Weibel ER: Morphometry of the Human Lung. Berlin, Springer, 1963.
- Gladstone IM Jr, Levine RL: Oxidation of proteins in neonatal lungs. Pediatrics 1994;93:764–768.
- Willet KE, Jobe AH, Ikegami M, Newnham J, Brennan S, Sly PD: Antenatal endotoxin and glucocorticoid effects on lung morphometry in preterm lambs. Pediatr Res 2000;48:R782–R788.
- Ueda K, Cho K, Matsuda T, Okajima S, Uchida M, Kobayashi Y, Minakami H, Kobayashi K: A rat model for arrest of alveolarization induced by antenatal endotoxin administration. Pediatr Res 2006;59:R396–R400.
- Frank L: Developmental aspects of experimental pulmonary oxygen toxicity. Free Radic Biol Med 1991;11:463–494.
- Kramer BW, Kramer S, Ikegami M, Jobe AH: Injury, inflammation, and remodeling in fetal sheep lung after intra-amniotic endotoxin. Am J Physiol 2002;283:L452–L459.
- Speer CP: Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med 2006;11:354–362.
- Choi CW, Kim BI, Kim HS, Park JD, Choi JH, Son DW: Increase of interleukin-6 in tracheal aspirate at birth: a predictor of subsequent bronchopulmonary dysplasia in preterm infants. Acta Paediatr 2006;95:38–43.
- Kotecha S, Wilson L, Wangoo A, Silverman M, Shaw RJ: Increase in IL-1β and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res 1996;40:R250–R256.
- Brettell LM, McGowan SE: Basic fibroblast growth factor decreases elastin production by neonatal rat lung fibroblasts. Am J Respir Cell Mol Biol 1994;10:306–315.
- Powers MR, Planck SR, Berger J, Wall MA, Rosenbaum JT: Increased expression of basic fibroblast growth factor in hyperoxic-injured mouse lung. J Cell Biochem 1994;56:536–543.
- Ambalavanan N, Novak ZE: Peptide growth factors in tracheal aspirates of mechanically ventilated preterm neonates. Pediatr Res 2003;53:240–244.
- Mitchell GB, Albright BN, Caswell JL: Effect of interleukin-8 and granulocyte colony-stimulating factor on priming and activation of bovine neutrophils. Infect Immun 2003;71:1643–1649.
- DeLeo FR, Renee J, McCormick S, Nakamura M, Apicella M, Weiss JP, Nauseef WM: Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase assembly. J Clin Invest 1998;101:455–463.
- Cheah FC, Jobe AH, Moss TJ, Newnham JP, Kallapur SG: Oxidative stress in fetal lambs exposed to intra-amniotic endotoxin in a chorioamnionitis model. Pediatr Res 2008;63:R274–R279.
- Kotecha S, Wangoo A, Silverman M, Shaw RJ: Increase in the concentration of transforming growth factor β1 in bronchoalveolar lavage fluid before development of chronic lung disease of prematurity. J Pediatr 1996;128:464–469.
- Lecart C, Cayabyab R, Buckley S, Morrison J, Kwong KY, Warburton D, Ramanathan R, Jones CA, Minoo P: Bioactive transforming growth factor-β in the lungs of extremely low birthweight neonates predicts the need for home oxygen supplementation. Biol Neonate 2000;77:217–223.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.